Analysts at Piper Jaffray upgraded Vertex Pharmaceuticals VRTX from Neutral to Overweight.
The price target for Vertex Pharmaceuticals has been raised from $87.50 to $125.
Vertex Pharma shares have gained 42.08% over the past 52 weeks, while the S&P 500 index has surged 11.46% in the same period.
Vertex Pharmaceuticals' shares fell 0.51% to close at $104.73 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in